Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID +1.05%48 3-Year Share Buyback Ratio is -22.70 as of Mar. 2026. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $7.41 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,196 Biotechnology companies, Ovid Therapeutics ranks worse than 66.72% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Ovid Therapeutics's current 3-Year Share Buyback Ratio was -22.70%.
The historical rank and industry rank for Ovid Therapeutics's 3-Year Share Buyback Ratio or its related term are showing as below:
OVID'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -41.8 Med: -15.75 Max: -0.1
Current: -22.7
During the past 11 years, Ovid Therapeutics's highest 3-Year Share Buyback Ratio was -0.10%. The lowest was -41.80%. And the median was -15.75%.
OVID's 3-Year Share Buyback Ratio is ranked worse than 66.72% of 1196
companies
in the Biotechnology industry
Industry Median: -11.75
vs OVID: -22.70
Ovid Therapeutics (NAS:OVID) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Ovid Therapeutics 3-Year Share Buyback Ratio Related Terms
OVID vs ARTV, CCCC, RZLT: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Ovid Therapeutics's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's 3-Year Share Buyback Ratio falls into.
Ovid Therapeutics 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -22.70 mean?
Ovid Therapeutics (OVID) has a 3-Year Share Buyback Ratio of -22.70 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #798 out of 1196 companies in the Biotechnology industry, placing it in the top 66.7%.
Is Ovid Therapeutics' 3-Year Share Buyback Ratio too high?
Ovid Therapeutics' current 3-Year Share Buyback Ratio is -22.70. Based on the distribution chart, Ovid Therapeutics ranks #798 out of 1196 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' 3-Year Share Buyback Ratio compare to ARTV and CCCC?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #798 out of 1196 companies for 3-Year Share Buyback Ratio. This places Ovid Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Ovid Therapeutics and its competitors. Ovid Therapeutics's current 3-Year Share Buyback Ratio is -22.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $7.41, compared to a current price of $2.40 — trading 67.6% below its estimated fair value. The current 3-Year Share Buyback Ratio is -22.70. Ovid Therapeutics' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current 3-Year Share Buyback Ratio is -22.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued.
The current stock price of $2.40 is trading 67.6% below its estimated GF Value™ of $7.41.
GuruFocus considers Ovid Therapeutics to be Possible Value Trap.
Key valuation signals for OVID:
3-Year Share Buyback Ratio: -22.70
GF Value™: $7.41 vs. price of $2.40 (67.6% below fair value)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score
Get the complete analysis for OVID
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
